The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).
Amar J. Gajjar
No relevant relationships to disclose
Sridharan Gururangan
No relevant relationships to disclose
Ibrahim A Qaddoumi
No relevant relationships to disclose
Roger Packer
No relevant relationships to disclose
Stewart Goldman
Consultant or Advisory Role - Novartis
Michael Prados
No relevant relationships to disclose
Annick Desjardins
No relevant relationships to disclose
Maryam Fouladi
No relevant relationships to disclose
Naoko Takebe
No relevant relationships to disclose
Shaoyi Li
No relevant relationships to disclose
David W. Ellison
No relevant relationships to disclose
Tom Curran
No relevant relationships to disclose
Richard J. Gilbertson
No relevant relationships to disclose
James M. Boyett
No relevant relationships to disclose